The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2025 | Emerging therapies for multiple myeloma and excitement in the GPRC5D space
Binod Dhakal, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the recent excitement in the GPRC5D space, highlighting the approved bispecific antibody talquetamab and promising data from patients treated with arlocabtagene autoleucel (arlo-cel). Dr Dhakal also outlines additional developments, including an FCRH5-targeting bispecific, the novel BCL2 inhibitor sonrotoclax for t(11:14) patients, and emerging protein degraders. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So of course we have the GPRC5D bispecific antibody which has already been approved, talquetamab, and you just mentioned GPRC5D CAR is arlo-cel – that data is quite convincing. You know the long-term follow-up data you saw at ASH you know median PFS of 19 months and more importantly they also allow patients with a prior BCMA CAR-T and BCMA-treated patients, and even in them the PFS is 19 months or almost 18 months, which is quite impressive data...
So of course we have the GPRC5D bispecific antibody which has already been approved, talquetamab, and you just mentioned GPRC5D CAR is arlo-cel – that data is quite convincing. You know the long-term follow-up data you saw at ASH you know median PFS of 19 months and more importantly they also allow patients with a prior BCMA CAR-T and BCMA-treated patients, and even in them the PFS is 19 months or almost 18 months, which is quite impressive data. So I’m really looking forward to this going to the next level is already happening. The Phase II pivotal trial is already running. And I’m very excited to have that available for the patients.
In addition, you know, there is another target called FcRH5, which is the bispecific antibody being explored there. The data we saw looks convincing, especially in the post-BCMA relapsed patients, post-BCMA CAR-T and the bispecific treated patients.
In addition, there are other molecules that I’m excited about, for example the novel BCL2 inhibitor for 11;14 patients. We’re doing a trial with the new BCL2 called sonrotoclax in that subgroup of patients and what we are seeing is quite fascinating results in terms of both efficacy and safety. And also there’s a new novel protein degraders that are being developed for example you know more target specific like targeting 4;14 patients with NSD2 inhibitor and similarly the more novel degraders of the proteins like IKZF degraders like you know mezigdomide and cemsidomide so these all are very exciting development in myeloma right now
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
